Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2002;106:2104-2110
Published online before print October 7, 2002, doi: 10.1161/01.CIR.0000034048.38910.91
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
106/16/2104    most recent
01.CIR.0000034048.38910.91v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pruefer, D.
Right arrow Articles by Buerke, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pruefer, D.
Right arrow Articles by Buerke, M.
Related Collections
Right arrow Animal models of human disease
Right arrow Cell biology/structural biology
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Other Vascular biology
Right arrowRelated Article

(Circulation. 2002;106:2104.)
© 2002 American Heart Association, Inc.


Basic Science Reports

Simvastatin Inhibits Inflammatory Properties of Staphylococcus aureus {alpha}-Toxin

Diethard Pruefer, MD; Joachim Makowski; Martin Schnell; Ute Buerke, MD; Manfred Dahm, MD; Hellmut Oelert, MD; Ulf Sibelius, MD; Ulrich Grandel, MD; Friedrich Grimminger, MD; Werner Seeger, MD; Jürgen Meyer, MD; Harald Darius, MD; Michael Buerke, MD

From the Department of Cardiothoracic and Vascular Surgery (D.P., J.M., M.D., H.O.) and Department of Medicine–Cardiology (M.S., U.B., J.M., H.D., M.B.), Johannes Gutenberg-University, Mainz, and Department of Medicine II (U.S., U.G., F.G., W.S.), Justus Liebig University, Giessen, Germany.

Correspondence to Michael Buerke, MD, Department of Medicine III, Martin-Luther-University, Ernst-Grube-Str. 40, 06120 Halle, Germany. E-mail michael.buerke{at}medizin.uni-halle.de

Background— Simvastatin, a 3-hydroxy-methylglutaryl coenzyme A reductase inhibitor, has been shown to lower serum cholesterol levels in clinical use. Moreover, statins exert beneficial effects in vascular diseases by inhibition of leukocyte rolling, adherence, and transmigration. The aim of this study was to determine if pretreatment with simvastatin attenuates Staphylococcus aureus {alpha}-toxin–induced increase in leukocyte-endothelial interactions during exotoxemia.

Methods and Results— The effects of simvastatin on leukocyte-endothelial cell interactions were observed by intravital microscopy in the rat mesenteric microcirculation. Simvastatin (50 or 100 µg/kg) was administered 18 hours before the study. Activation of microcirculation was induced by bolus administration of 40 µg/kg S aureus {alpha}-toxin. Exotoxemia resulted in a significant and time-dependent increase in leukocyte rolling, adherence, and transmigration of leukocytes as well as P-selectin expression on the intestinal vascular endothelium. Pretreatment with simvastatin significantly inhibited exotoxin-induced leukocyte rolling from 71±10 to 14±4.7 cells/min (P<0.01) and adherence from 14±3.5 to 0.4±0.2 cells (P<0.01). In addition, simvastatin pretreatment significantly inhibited transmigration of leukocytes from 10.5±1.2 to 4.2±0.9 (P<0.05) cells. Immunohistochemical detection of endothelial cell adhesion molecule P-selectin showed a 50% decrease in endothelial cell surface expression after simvastatin treatment. Furthermore, simvastatin treatment resulted in enhanced expression of endothelial cell NO synthase III in the intestinal microcirculation.

Conclusions— These results demonstrate that simvastatin interferes with exotoxin-induced leukocyte-endothelial cell interactions, which may be relevant in various infectious diseases. Statin treatment may offer a new therapeutic strategy for these clinical conditions.


Key Words: statins • endothelium • inflammation • microcirculation


Related Article:

Statins as Potent Antiinflammatory Drugs
David J. Lefer
Circulation 2002 106: 2041-2042. [Extract] [Full Text]



This article has been cited by other articles:


Home page
Arch Intern MedHome page
I. M. Tleyjeh, T. Kashour, F. A. Hakim, V. A. Zimmerman, P. J. Erwin, A. J. Sutton, and T. Ibrahim
Statins for the Prevention and Treatment of Infections: A Systematic Review and Meta-analysis
Arch Intern Med, October 12, 2009; 169(18): 1658 - 1667.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
B. Vollmar and M. D. Menger
The Hepatic Microcirculation: Mechanistic Contributions and Therapeutic Targets in Liver Injury and Repair
Physiol Rev, October 1, 2009; 89(4): 1269 - 1339.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
N. Daneman, D. Thiruchelvam, and D. A. Redelmeier
Statin Use and the Risk of Surgical Site Infections in Elderly Patients Undergoing Elective Surgery
Arch Surg, October 1, 2009; 144(10): 938 - 945.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
F. Gao, L. Linhartova, A. McD. Johnston, and D. R. Thickett
Statins and sepsis
Br. J. Anaesth., March 1, 2008; 100(3): 288 - 298.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. Suzuki, Z.-G. Jin, D. F. Meoli, T. Matoba, and B. C. Berk
Cyclophilin A Is Secreted by a Vesicular Pathway in Vascular Smooth Muscle Cells
Circ. Res., March 31, 2006; 98(6): 811 - 817.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
L. Erkkila, M. Jauhiainen, K. Laitinen, K. Haasio, T. Tiirola, P. Saikku, and M. Leinonen
Effect of Simvastatin, an Established Lipid-Lowering Drug, on Pulmonary Chlamydia pneumoniae Infection in Mice
Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3959 - 3962.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Pleiner, G. Schaller, F. Mittermayer, S. Zorn, C. Marsik, S. Polterauer, S. Kapiotis, and M. Wolzt
Simvastatin Prevents Vascular Hyporeactivity During Inflammation
Circulation, November 23, 2004; 110(21): 3349 - 3354.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. Miyahara, J. Kiryu, K. Yamashiro, K. Miyamoto, F. Hirose, H. Tamura, H. Katsuta, K. Nishijima, A. Tsujikawa, and Y. Honda
Simvastatin Inhibits Leukocyte Accumulation and Vascular Permeability in the Retinas of Rats with Streptozotocin-Induced Diabetes
Am. J. Pathol., May 1, 2004; 164(5): 1697 - 1706.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. M Ridker and on behalf of the JUPITER Study Group
Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial*
Circulation, November 11, 2003; 108(19): 2292 - 2297.
[Full Text] [PDF]


Home page
CirculationHome page
D. J. Kereiakes
Adjunctive Pharmacotherapy before Percutaneous Coronary Intervention in Non-ST-Elevation Acute Coronary Syndromes: The Role of Modulating Inflammation
Circulation, October 21, 2003; 108(90161): III-22 - 27.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
W. Balduini, E. Mazzoni, S. Carloni, M. G. De Simoni, C. Perego, L. Sironi, and M. Cimino
Prophylactic but Not Delayed Administration of Simvastatin Protects Against Long-Lasting Cognitive and Morphological Consequences of Neonatal Hypoxic-Ischemic Brain Injury, Reduces Interleukin-1{beta} and Tumor Necrosis Factor-{alpha} mRNA Induction, and Does Not Affect Endothelial Nitric Oxide Synthase Expression
Stroke, August 1, 2003; 34(8): 2007 - 2012.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. J. Lefer
Statins as Potent Antiinflammatory Drugs
Circulation, October 15, 2002; 106(16): 2041 - 2042.
[Full Text] [PDF]